Method of sequence-independent quantification of proteolytically unstable plasma lambda free light chain protein for al amyloidosis diagnosis

HK40137348APending Publication Date: 2026-09-11PROTEGO BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124410
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-08
Filing Date
2026-06-05
Publication Date
2026-09-11
Patent Text Reader

Abstract

A method for combining limited proteolysis and immunoassays for the specific detection and quantification of amyloidogenic XFLC in biofluids. The method is enabled by using mAbs that are capable of detecting and quantifying neo-epitopes on the dLCCD biomarker, generated after limited proteolysis of ZFLC. which heavily favors kinetically unstable, or amyloidogenic, LFLC. This method is independent of FLC primary sequences in the variable and constant domains and can be used on the detection and quantification of up to 99% of human XFLC. The clinical utilities of the assay include early detection in individuals suspected of plasma cell disorders (MGUS, SMM, MM, IgM-AL, and AL), differentiation from other amyloidosis such as ATTR, use in companion diagnostics, demonstration of target engagement, assessment of therapeutic response, detection of MRD, detection of relapse. Assays that quantify the resulting dLCCD biomarker and / or that can further improve the assay's sensitivity, such as MSD, lateral flow, mass spectrometry, are also embodied.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract: A method for the specific detection and quantification of amyloid-derived XFLC in biofluids by combining restriction proteolysis and immunoassay. This method utilizes an mAb capable of detecting and quantifying novel epitopes on dLCCD biomarkers generated after restriction proteolysis of ZFLC, which is highly advantageous for kinetically unstable or amyloid-derived LFLC. The method is independent of the primary sequence of FLC in variable and constant domains and can be used to detect and quantify up to 99% of human XFLC. Clinical applicability of this assay includes early detection in individuals suspected of having plasma cell disorders (MGUS, SMM, MM, IgM-AL, and AL), differentiation from other amyloidosis such as ATTR, use in companion diagnostics, demonstration of target binding, assessment of treatment response, detection of MRD, and detection of relapse. Quantification of the resulting dLCCD biomarkers and / or assays that can further improve assay sensitivity, such as MSD, lateral flow, and mass spectrometry, have also been implemented.

Claims

WHAT IS CLAIMED IS:

1. A method of generating a monoclonal antibody for detection of a neo-epitope formed from amyloidogenic λ free light chain (λFLC) proteins, comprising the steps of:(a) proteolyzing a sample comprising λ free light chain (λFLC) proteins with proteinase K, wherein the proteolyzing results in a neo-epitope exposed on the N-terminal of a ~23KDa fragment comprising at least part of the constant domain of the λFLC, or when λFLC is a monomer, a neo-epitope exposed on the N-terminal of a ~11.5 KDa fragment comprising at least part of the constant domain of the λFLC proteins; and wherein the neo-epitope is xQP, where x is one of G, R or S (G=Glycine, R= Arginine, S=Serine); and(b) generating a monoclonal antibody to the neo-epitope on the fragment of the λFLC, wherein the generated monoclonal antibody (LCCD) specifically binds to the neo-epitope of xQP, and wherein proteolyzing conditions are optimized so that an LCCD signal obtained after proteolyzing from the ~23KDa fragment, or the ~11.5 KDa fragment, is at least two times stronger from an amyloidogenic λFLC compared to a non-amyloidogenic λFLC.

2. The method of Claim 1, wherein the neo-epitope is GQP.

3. The method of Claim 1 , wherein the neo-epitope is RQP.

4. The method of Claim 1, wherein the neo-epitope is SQP.

5. The method of Claim 2, wherein the generated antibody (LCCD-G) binds to the neoepitope of GQP.

6. The method of Claim 3, wherein the generated antibody (LCCD-R) binds to the neoepitope of RQP.

7. The method of Claim 4, wherein the generated antibody (LCCD-S) binds to the neoepitope of SQP.

8. The method of any one of Claims 1-7, wherein the fragment of the λFLC is a homodimeric fragment, which is a ~23kDa fragment under non-denaturing condition.

9. The method of any one of Claims 1-7, wherein the fragment of the λFLC is a monomeric fragment, which is a ~11.5kDa fragment under denaturing condition.

10. The method of any one of Claims 1-9. wherein the limited proteolysis by proteinase K comprises the steps of: a liquid sample treated with an optimized proteolysis condition to produce the LCCD domain.

11. The method of any one of Claims 1-10, wherein the optimized proteolysis condition is 0.02-20. OpM Proteinase K at 37°C for 30 seconds to 20 hours depending on the specific activity of the protease.

12. An antibody for detection of a neo-epitope formed from amyloidogenic λ free light chain (λFLC) proteins, wherein the antibody comprises heavy chain encoded by a nucleotide sequence of LCCD-G SEQ.ID. No.: 4 (HC3) and light chain encoded by a nucleotide sequence of LCCD-G SEQ.ID. No.:5 (LC7).

13. An antibody for detection of a neo-epitope formed from amyloidogenic λ free light chain (λFLC) proteins, wherein the antibody comprises heavy chain encoded by a nucleotide sequence of LCCD-S SEQ.ID. No.: 8 (HC2) and light chain encoded by a nucleotide sequence of LCCD-S SEQ ID No: 9 (LC5).

14. An antibody for detection of a neo-epitope formed from amyloidogenic λ free light chain (λFLC) proteins, wherein the antibody is encoded by a nucleotide sequence encoding LCCD-S (SEQ.ID. No.: 8 (HC2) and SEQ ID No: 9 (LC5)).

15. A method of assessing target engagement of a FLC stabilizer for treatment of light chain amyloidosis, comprising the steps of: limited proteolysis of proteins from a biological sample,wherein the biological sample is a recombinant protein or from a subject receiving treatment by a targeted therapeutic molecule for light chain amyloidosis, and wherein the limited proteolysis results in a neo-epitope exposed on a LCCD fragment of the λFLC proteins; detecting the presence of the neo-epitope on an N-termini of the LCCD fragment of the λFLC proteins; and quantitating the level of the fragment of the λFLC proteins resulting from the limited proteolysis based on the neo-epitope presence detected, wherein target engagement is assessed by comparing a first level of quantity of the LCCD fragment present before the targeted therapeutic molecule has been introduced to the subject, or to a sample from a subject ex vivo, to a second level of quantity of the LCCD fragment present after the targeted therapeutic molecule has been introduced to the subject, or to a sample from a subject ex vivo, wherein a reduction in the LCCD level, or the LCCD level normalized to the total λFLC in the second level of quantification indicates target engagement.

16. A method of assessing therapeutic response of a therapeutics for treatment of light chain amyloidosis by quantifying a LCCD fragment in plasma samples before and after the therapeutic molecule has been introduced to the subject, or at two different time points during the treatment, wherein a reduction in the post-treatment or second timepoint level of LCCD indicates favorable response to the therapeutic molecule, irrespective to the total level of λFLC.

17. A method of assessing if an AL patient would benefit from a light chain stabilizer as a therapy by quantifying a LCCD fragment in plasma samples from a subject being considered to receive treatment by a light chain stabilizer molecule for light chain amyloidosis, wherein the ex vivo plasma sample is incubated with the said stabilizer or a solvent control, before subjecting the samples to limited proteolysis, and quantification of the resulting LCCD levels, wherein a reduction of LCCD level in the sample that was incubated with the stabilizer versus the solvent control sample indicates the subject may benefit from treatment by the said light chain stabilizer.

18. The method of any one of Claims 15-17, wherein when the first level of the LCCD fragment present before the targeted therapeutic molecule has been introduced to the subjectis greater than the second level of the LCCD fragment present after the targeted therapeutic molecule has been introduced to the subject, then target engagement has occurred by the targeted therapeutic molecule.

19. The method of any one of Claims 15-17, wherein when the first level of the LCCD fragment present before the targeted therapeutic molecule has been introduced to the subject is the same or less than the second level of the LCCD fragment present after the targeted therapeutic molecule has been introduced to the subject, then target engagement has not occurred by the targeted therapeutic molecule.

20. The method of any one of Claim 15-19, wherein the biological sample is one of plasma, urine, serum, cerebrospinal fluid (CSF), or tissue biopsy.

21. A method of detection of presence in a subject of amyloidogenic λ free light chain ( λFLC) proteins, comprising the steps of: limited proteolysis of proteins from a biological sample, wherein the limited proteolysis results in a neo-epitope exposed on a LCCD fragment of the λFLC proteins; detecting the presence of the neo-epitope on the N-termini of the LCCD fragment of the λFLC proteins; quantitating the presence of the LCCD fragment from the λFLC proteins based on measuring the level of neo-epitope on the fragment using the LCCD mAbs; and comparing levels of the LCCD fragment before and after the limited proteolysis, wherein when the level of the LCCD fragment from λFLC proteins is greater after limited proteolysis, then amyloidogenicx yTLC proteins are detected.

22. The method of Claim 21, further comprising the steps of: measuring a first level of the LCCD fragment of the ZFI .C proteins present after the limited proteolysis in a biological sample taken from a healthy subject not having light chain amyloidosis (AL), wherein the first level is a reference level; measuring a second level of the fragment of the λFLC proteins present after the limited proteolysis of a biological sample from a person suspected of having AL; andwherein when the second level of the LCCD fragment of the λFLC proteins after the limited proteolysis of the biological sample is greater than the reference level, then amyloidogenic λFLC proteins are detected.

23. The method of any one of Claims 21-22, wherein when the level of LCCD fragment from λFLC is detected after limited proteolysis by Proteinase K and at an elevated level above the reference level, then light chain amyloidosis is present in the subject.

24. The method of Claim 23, where an elevated LCCD fragment level in a subject leads to a clinical decision, wherein the clinical decision is treatment and management for light chain amyloidosis (AL).

25. The method of Claim 23, where absence of an elevated LCCD fragment level in a subject leads to a clinical decision, wherein the clinical decision is ruling out of AL diagnosis and receiving treatment for other systemic amyloidosis, wherein the other systemic amyloidosis may include transthyretin amyloidosis (ATTR).

26. The method of any one of Claims 21-25, wherein the LCCD fragment is a 23KDa homodimer and is detected and quantified using mass spectrometry.

27. The method of any one of Claims 21 -25, wherein the LCCD fragment is a 11 5KDa monomer and is detected and quantified using mass spectrometry.

28. The method of any one of Claims 21-27, wherein the subject has one of more of clinical suspicion of amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple myeloma (MM), Light Chain Amyloidosis (AL), Smoldering Multiple Myeloma (SMM), IgM light chain amyloidosis, Minimal Residual Disease (MRD) of AL, and Relapse of AL.

29. The method of any one of Claims 21-28, wherein the biological sample is one of plasma, urine, serum, CSF, or tissue biopsy.

30. A kit for detection of presence in a subject of amyloidogenic λ free light chain (λFLC) proteins, comprising:the antibodies of LCCD-G, LCCD-R and LCCD-S; instructions for using the kit in accordance with the method of Claim 21.

31. A neo-epitope on λFLC prepared by limited proteolysis of amyloidogenic λ free light chain (λFLC) proteins by proteinase K.

32. The neo-epitope of claim 31 that is xQP. where x is one of G. R or S.

33. An antibody or antibody mixture to the neo-epitope of claim 31 or 32.

34. The antibody of claim 33 that is LCCD-G. LCCD-R or LCCD-S.

35. A method of optimizing limited proteolysis condition using Proteinase K, comprising the steps of optimizing one or more of the following enumerated factors:(1) source of the Proteinase K;(2) composition of the testing sample;(3) concentration of Proteinase K;(4) time of proteolysis reaction;(5) temperature of proteolysis reaction; wherein a proteolysis product of the LCCD fragment is differentially obtained from amyloidogenic λFLC vs. non-amyloidogenic λFLC.

36. The method of detection of presence in a subject of amyloidogenic λ free light chain (λFLC) proteins of any one of Claims 21-29, further comprising: obtaining a readout from an LCCD signal obtained by measuring the level of neo-epitope on the fragment using the LCCD mAbs.

37. The method of detection of presence in a subject of amyloidogenic λ free light chain(λFLC) proteins of Claim 36, further comprising: obtaining the readout of the LCCD signal by use of an algorithm.